Diadema Partners’s Aprea Therapeutics APRE Stock Holding History

Diadema Partners’s Portfolio APRE Stock Details APRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$36K	Buy	+44,907	New	+$37.5K	﹤0.01%	141

Other funds holding APRE

ACM

AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3B AUM 119.43% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Diadema Partners's APRE Position: Q2 2026 in Review

Diadema Partners opened a new position in Aprea Therapeutics (APRE) in Q2 2026: 44,907 shares worth $36K. The stake represents ﹤0.01% of the portfolio and ranks #141 among its holdings.

26 funds tracked by Wall St. Rank hold APRE as of Q2 2026.

Diadema Partners held 44,907 shares of Aprea Therapeutics worth $36K as of Q2 2026.
Aprea Therapeutics was a new Diadema Partners position in Q2 2026.
Aprea Therapeutics made up ﹤0.01% of Diadema Partners's portfolio in Q2 2026, its #141 holding.
26 funds tracked by Wall St. Rank held Aprea Therapeutics as of Q2 2026.

Based on Diadema Partners's 13F filing for Q2 2026, filed 14 Aug 2026.